[go: up one dir, main page]

AR031679A1 - Una composicion farmaceutica - Google Patents

Una composicion farmaceutica

Info

Publication number
AR031679A1
AR031679A1 ARP000105669A ARP000105669A AR031679A1 AR 031679 A1 AR031679 A1 AR 031679A1 AR P000105669 A ARP000105669 A AR P000105669A AR P000105669 A ARP000105669 A AR P000105669A AR 031679 A1 AR031679 A1 AR 031679A1
Authority
AR
Argentina
Prior art keywords
pharmaceutical composition
pyrimidinyl
phenyletenesulfonamide
methoxyphenoxy
endothelin
Prior art date
Application number
ARP000105669A
Other languages
English (en)
Inventor
Hironori Yuyama
Masanao Sanagi
Hironori Harada
Akiko Koakutsu
Mikiko Mori
Nobuyuki Yamamoto
Akira Fujimori
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of AR031679A1 publication Critical patent/AR031679A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Una composicion farmacéutica para reducir el dolor en una enfermedad inducida por endotelina, la composicion farmacéutica que contiene N-[6-metoxi-5-(2-metoxifenoxi)-2-(2-pirimidinil)-4-pirimidinil]-2-feniletenosulfonamida o una sal farmacéuticamente aceptable de la misma como componente efectivo.
ARP000105669A 2000-02-16 2000-10-27 Una composicion farmaceutica AR031679A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000037313 2000-02-16
JP2000037314 2000-02-16

Publications (1)

Publication Number Publication Date
AR031679A1 true AR031679A1 (es) 2003-10-01

Family

ID=26585418

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000105669A AR031679A1 (es) 2000-02-16 2000-10-27 Una composicion farmaceutica

Country Status (15)

Country Link
US (1) US6774131B1 (es)
EP (1) EP1256344B1 (es)
JP (2) JP3832229B2 (es)
KR (1) KR20020075797A (es)
CN (1) CN1434715A (es)
AR (1) AR031679A1 (es)
AT (1) ATE348617T1 (es)
AU (1) AU2000279614A1 (es)
BR (1) BR0017120A (es)
CA (1) CA2395711A1 (es)
DE (1) DE60032517T2 (es)
ES (1) ES2277856T3 (es)
HU (1) HUP0204139A3 (es)
RU (1) RU2002124599A (es)
WO (1) WO2001060370A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0011903D0 (en) * 2000-05-18 2000-07-05 Astrazeneca Ab Combination chemotherapy
GB0219660D0 (en) * 2002-08-23 2002-10-02 Astrazeneca Ab Therapeutic use
GB0403744D0 (en) 2004-02-20 2004-03-24 Astrazeneca Ab Chemical process
US8173686B2 (en) 2006-11-06 2012-05-08 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8178564B2 (en) * 2006-11-06 2012-05-15 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8168662B1 (en) 2006-11-06 2012-05-01 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8168661B2 (en) * 2006-11-06 2012-05-01 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
EP2114418A4 (en) * 2007-02-09 2013-01-09 Poniard Pharmaceuticals Inc ORAL DOSAGE FORM WITH STABILIZED PICOPLATIN
US20110033528A1 (en) * 2009-08-05 2011-02-10 Poniard Pharmaceuticals, Inc. Stabilized picoplatin oral dosage form
US20100260832A1 (en) * 2007-06-27 2010-10-14 Poniard Pharmaceuticals, Inc. Combination therapy for ovarian cancer
TW200916094A (en) * 2007-06-27 2009-04-16 Poniard Pharmaceuticals Inc Stabilized picoplatin dosage form
US20100310661A1 (en) * 2007-07-16 2010-12-09 Poniard Pharmaceuticals, Inc. Oral formulations for picoplatin
EP2244714A4 (en) * 2008-02-08 2012-06-06 Poniard Pharmaceuticals Inc USE OF PICOPLATIN AND BEVACIZUMAB TO TREAT COLORECTAL CANCER
EP2294056A1 (en) * 2008-05-23 2011-03-16 Synthon B.V. Bosentan salts
CN104995313A (zh) 2012-10-12 2015-10-21 生物运动有限公司 使用c-maf的前列腺癌转移的诊断、预后和治疗的方法
US10119171B2 (en) 2012-10-12 2018-11-06 Inbiomotion S.L. Method for the diagnosis, prognosis and treatment of prostate cancer metastasis

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0882719B1 (en) * 1995-12-20 2001-05-16 Yamanouchi Pharmaceutical Co. Ltd. Arylethenesulfonamide derivatives and drug composition containing the same
US6030975A (en) 1997-03-14 2000-02-29 Basf Aktiengesellschaft Carboxylic acid derivatives, their preparation and use in treating cancer
US6673832B1 (en) * 1998-05-04 2004-01-06 Gudarz Davar Methods for identifying compounds for treating pain

Also Published As

Publication number Publication date
DE60032517T2 (de) 2007-10-04
HUP0204139A3 (en) 2003-07-28
CA2395711A1 (en) 2002-07-18
JP3832229B2 (ja) 2006-10-11
BR0017120A (pt) 2003-01-14
EP1256344B1 (en) 2006-12-20
JP2006176542A (ja) 2006-07-06
DE60032517D1 (de) 2007-02-01
KR20020075797A (ko) 2002-10-05
HUP0204139A2 (en) 2003-05-28
RU2002124599A (ru) 2004-03-10
CN1434715A (zh) 2003-08-06
ATE348617T1 (de) 2007-01-15
AU2000279614A1 (en) 2001-08-27
EP1256344A4 (en) 2004-12-29
WO2001060370A1 (fr) 2001-08-23
US6774131B1 (en) 2004-08-10
EP1256344A1 (en) 2002-11-13
JP2001302514A (ja) 2001-10-31
ES2277856T3 (es) 2007-08-01

Similar Documents

Publication Publication Date Title
AR031679A1 (es) Una composicion farmaceutica
AR023624A1 (es) Composiciones farmaceuticas que comprenden un inhibidor de hmg coa reductasa
ECSP045102A (es) Formulación farmacéutica que contiene 3-(3-dimetilamino-1-etil-2-metil-propil)fenol y proporciona una liberación retardada del ingrediente activo
NO20011721D0 (no) N-aralkylaminotetraliner som ligander for neuropeptid Y Y5 reseptor
EA200601591A1 (ru) Применение рибонуклеозидных соединений для лечения флавивирусных и пестивирусных инфекций
ES2185606T3 (es) Nuevo uso de una clase de compuestos peptidicos para tratamiento de la alodinia u otros tipos diferentes de dolor cronico o fantasma.
NO20076613L (no) Farmasoytiske formuleringer og anvendelse derav
CL2007001918A1 (es) Compuestos derivados heteroarilos sustituidos; metodo para la preparacion de los compuestos; composicion farmaceutica; y uso para el tratamiento del dolor, depresion, enfermedad de alzheimer e hipertension entre otras.
CL2009001899A1 (es) Composicion farmaceutica que comprende: i) un antagonista del receptor de at1 o una sal, ii) un sensibilizante a la insulina o una sal y iii) un vehiculo farmaceuticamente aceptable; uso para la prevencion, demora de progreso o tratamiento de hipertension, diabetes, entre otras (div. sol. 2034-01).
CY1110906T1 (el) Φαρμακευτικη συνθεση για ρινικη χορηγηση φεντανυλης
AR056517A1 (es) Composiciones y metodos farmaceuticos utilizando temozolomida y un inhibidor de la proteina quinasa
ES2421948T3 (es) Compuestos y composiciones para suministrar agentes activos
ATE499939T1 (de) Neue pharmazeutische zusammenstezungen, flibanserin polymorph a enthaltend
BR0112847A (pt) Uso de uma forma de dosagem sólida
AR031649A1 (es) Composicion farmaceutica de dronedarona para administracion parenteral
CO5261583A1 (es) Combinacion de farmacos para el tratamiento de la depresion y transtornos relacionados que comprende mirtazapina
UY27416A1 (es) Uso de bibn4096 en combinación con otros fármacos antimigranosos para el tratamiento de migrana
NO20065791L (no) Asyklovir-formuleringer
EA200702386A1 (ru) Твердая фармацевтическая композиция для продолжительного высвобождения 1-(2,3,4-триметоксибензил)пиперазина и способ ее получения
AR043016A2 (es) Un compuesto antimigranico eletriptan y composicion farmaceutica que lo contiene
AR037496A1 (es) Uso novedoso del 2-[5-(4-fluorofenil)-3-piridilmetilaminometil]-cromano y sus sales fisiologicamente aceptables
ATE400256T1 (de) Pharmazeutische zusammensetzung mit einem kationischen hilfsmittel
ATE357220T1 (de) Pharmazeutische zusammensetzung mit modifizierter freisetzung
ATE410154T1 (de) Pharmazeutische zusammensetzung enthaltend 2,4- dichlorbenzylalkohol und amylmetakresol
UY27920A1 (es) Combinaciones de epinastina, pseudoefedrina y metilefedrina como nuevas formulaciones farmaceuticas

Legal Events

Date Code Title Description
FA Abandonment or withdrawal